Market capitalization | $855.74m |
Enterprise Value | $775.73m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 33.39 |
P/S ratio (TTM) P/S ratio | 36.84 |
P/B ratio (TTM) P/B ratio | 11.12 |
Revenue growth (TTM) Revenue growth | 65.33% |
Revenue (TTM) Revenue | $23.23m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Capricor Therapeutics, Inc. forecast:
7 Analysts have issued a Capricor Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 23 23 |
65%
65%
|
|
Gross Profit | 22 22 |
67%
67%
|
|
EBITDA | -35 -35 |
16%
16%
|
EBIT (Operating Income) EBIT | -36 -36 |
16%
16%
|
Net Profit | -34 -34 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Head office | United States |
CEO | Linda Marbán |
Employees | 102 |
Founded | 1996 |
Website | www.capricor.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.